Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Viewpoint - Quantum BioPharma Ltd. has partnered with BitGo Trust Company to manage and store its cryptocurrency assets, including Bitcoin, Solana, XRP, and DOGE coin, enhancing its security and compliance as a public company [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [3]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [3]. - Quantum BioPharma retains a 22.95% ownership stake in Celly Nutrition Corp., which markets the product unbuzzd™, and is entitled to a 7% royalty on sales until total payments reach $250 million, after which the royalty will decrease to 3% [3]. Partnership with BitGo - BitGo will provide institutional-grade custody services, including multi-signature wallets and 100% cold storage technology, to protect Quantum's cryptocurrency assets from theft and unauthorized access [2]. - The partnership aligns with Quantum's priorities for security and compliance as it expands its engagement with cryptocurrency assets [2][3]. Industry Context - The collaboration with BitGo reflects a broader trend where institutions like Quantum are shaping the future of digital finance, emphasizing the need for secure and compliant infrastructure [3][5]. - BitGo is recognized as a leading provider of digital asset solutions, serving thousands of institutions and handling a significant portion of Bitcoin network transactions [5].

Group 1 - Quantum BioPharma Ltd. has closed the final tranche of its offering, raising a total of $5 million to advance research and development of innovative drug candidates and for general working capital purposes [1][2] - The company has developed a formulation for rekvry™, aimed at treating alcohol misuse in emergency and hospital settings, addressing an unmet need in healthcare [2] - Quantum BioPharma is focused on neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in preventing and reversing myelin degradation in preclinical models [3] Group 2 - The company retains a 25.71% ownership stake in Celly Nutrition, which markets the product UNBUZZD™, and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will drop to 3% [3] - Quantum BioPharma maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [3]